XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Loss and Other Comprehensive Income (Loss) ( Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues $ 31,916 $ 30,373
Cost of products sold 24,480 23,415
Gross profit 7,436 6,958
Operating expenses:    
Research and development 2,032 1,857
Selling, general and administrative 5,378 5,396
Total operating expenses 7,410 7,253
Operating income (loss) 26 (295)
Other (expense) income:    
Interest and financing expense (424) (134)
Miscellaneous (expense) income (70) 17
Total other expense (494) (117)
Loss before income taxes (468) (412)
Income tax benefit (133) (251)
Net loss (335) (161)
Net income attributable to non-controlling interest 11 7
Net loss attributable to Ultralife Corporation (346) (168)
Other comprehensive income (loss):    
Foreign currency translation adjustments 197 (236)
Comprehensive income (loss) attributable to Ultralife Corporation $ 149 $ (404)
Net loss per share attributable to Ultralife common shareholders – basic (in dollars per share) $ (0.02) $ (0.01)
Net loss per share attributable to Ultralife common shareholders – diluted (in dollars per share) $ (0.02) $ (0.01)
Weighted average shares outstanding – basic (in shares) 16,135 16,104
Potential common shares (in shares) 0 0
Weighted average shares outstanding - diluted (in shares) 16,135 16,104